Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447120 · ClinicalTrials.gov registry record
Topcon 3D OCT-1 Maestro Reference Database Study II
A clinical trial of Healthy, sponsored by Topcon Medical Systems.
- Completed
- Registry status
- 504
- Enrollment target
- 7
- Study locations
NCT02447120: Completed study of Healthy, sponsored by Topcon Medical Systems.
NCT02447120 is a study of Healthy that has completed, run by Topcon Medical Systems. The registered enrollment target is 504 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (22% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02447120, a study of Healthy, has completed, sponsored by Topcon Medical Systems.
- COMPLETED
- Registry status
- 504 participants
- Enrollment target
- 7
- Study locations
Study Summary
The objective of this study is to collect OCT measurement data on normal healthy eyes in order to determine the reference limits for Topcon 3D OCT-1 Maestro based on the percentile points for 1%, 5%, 95%, and 99%.
Conditions Studied
Interventions
- DEVICE 3D OCT-1 Maestro
Study Locations (7)
California
- Southern California College of Optometry - Fullerton
- Valley Eyecare Center - Livermore
- Western University of Health Sciences - Pomona
New York
- New York VA - Jamaica
- SUNY College of Optometry - New York
Alabama
- UAB School of Optometry - Birmingham
Illinois
- Illinois College of Optometry - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-10 |
What the finished NCT02447120 record still lists
NCT02447120 is an observational study that tracks outcomes without assigning an intervention. The registered 504 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which 3D OCT-1 Maestro is the first listed.
NCT02447120 lists 7 locations in 4 states (California, New York, Alabama).
Frequently Asked Questions
What is clinical trial NCT02447120 about?
NCT02447120 is a clinical study titled "Topcon 3D OCT-1 Maestro Reference Database Study II". The objective of this study is to collect OCT measurement data on normal healthy eyes in order to determine the reference limits for Topcon 3D OCT-1 Maestro based on the percentile points for 1%, 5%, 95%, and 99%.
What is the current status of trial NCT02447120?
This trial is currently completed. The enrollment target is 504 participants. The study started on 2015-05. Estimated completion is 2015-10.
What conditions does trial NCT02447120 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02447120?
The interventions under investigation include: 3D OCT-1 Maestro (DEVICE).
Who is sponsoring clinical trial NCT02447120?
This trial is sponsored by Topcon Medical Systems, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02447120 being conducted?
This trial has 7 study locations across Alabama, California, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02447120's enrollment target sits among peer trials
504 48th of 1090 higher than 1,043 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05846282 · 504 participants · NA
Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience
- NCT06072131 · 504 participants · Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
- NCT06736522 · 504 participants · NA
Future Leaders Program: Testing a Youth Leadership, Engagement, and Mindfulness Program
- NCT06822257 · 504 participants · NA
Drinking in Young Adult Duos (DYAD) Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia